Cargando…

CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy

Chimeric antigen receptor (CAR)-engineered T lymphocytes (CAR Ts) produced impressive clinical results against selected hematological malignancies, but the extension of CAR T cell therapy to the challenging field of solid tumors has not, so far, replicated similar clinical outcomes. Many efforts are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rotolo, Ramona, Leuci, Valeria, Donini, Chiara, Cykowska, Anna, Gammaitoni, Loretta, Medico, Giovanni, Valabrega, Giorgio, Aglietta, Massimo, Sangiolo, Dario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600566/ https://www.ncbi.nlm.nih.gov/pubmed/31212634 http://dx.doi.org/10.3390/ijms20112839

Ejemplares similares

Cellular Immunotherapy Targeting Cancer Stem Cells: Preclinical Evidence and Clinical Perspective
por: Donini, Chiara, et al.
Publicado: (2021)

Adoptive immunotherapy against ovarian cancer
por: Mittica, Gloria, et al.
Publicado: (2016)

Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti‐leukaemic potential and alloreactivity across major human leukocyte antigen barriers
por: Circosta, Paola, et al.
Publicado: (2022)

CD44v6 as innovative sarcoma target for CAR-redirected CIK cells
por: Leuci, V., et al.
Publicado: (2018)

Activity of cytokine-induced killer cells against bone and soft tissue sarcoma
por: Sangiolo, Dario, et al.
Publicado: (2014)

CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma
por: Giraudo, Lidia, et al.
Publicado: (2023)

Recent advances in the development of breast cancer vaccines
por: Milani, Andrea, et al.
Publicado: (2014)

Cytokine Induced Killer cells effectively kill chemo-resistant melanoma cancer stem cells
por: Gammaitoni, Loretta, et al.
Publicado: (2015)

Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy.
por: Mesiano, Giulia, et al.
Publicado: (2018)

Adoptive Immunotherapy beyond CAR T-Cells
por: Titov, Aleksei, et al.
Publicado: (2021)

Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST
por: Fiorino, Erika, et al.
Publicado: (2022)

Recruitment, Infiltration, and Cytotoxicity of HLA-Independent Killer Lymphocytes in Three-Dimensional Melanoma Models
por: Iaia, Ilenia, et al.
Publicado: (2021)

Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy
por: Chiriaco, Cristina, et al.
Publicado: (2022)

Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1(+) Chemoresistant Lung Cancer Cells
por: Rotolo, Ramona, et al.
Publicado: (2023)

Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T
por: Liu, Qiaofei, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?
por: Mittica, Gloria, et al.
Publicado: (2016)

Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer
por: Capellero, S., et al.
Publicado: (2020)

Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy
por: Merlano, Marco Carlo, et al.
Publicado: (2021)

Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity
por: Leuci, V., et al.
Publicado: (2016)

Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours
por: Martin, Valentina, et al.
Publicado: (2019)

Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors
por: Sloas, Christopher, et al.
Publicado: (2021)

Opportunities for CAR-T Cell Immunotherapy in HIV Cure
por: Campos-Gonzalez, Gerard, et al.
Publicado: (2023)

Development of CAR-T Cell Persistence in Adoptive Immunotherapy of Solid Tumors
por: Fan, Jiaqiao, et al.
Publicado: (2021)

CAR T Cell Immunotherapy Beyond Haematological Malignancy
por: Hupperetz, Cedric, et al.
Publicado: (2022)

Cytokine Induced Killer Cells as Promising Immunotherapy for Solid Tumors
por: Sangiolo, Dario
Publicado: (2011)

CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities
por: Ren, Anqi, et al.
Publicado: (2023)

Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma
por: Yi, Zhongzhen, et al.
Publicado: (2018)

Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models
por: Peraldo-Neia, Caterina, et al.
Publicado: (2014)

EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing’s Sarcoma and Chondrosarcoma
por: Giordano, Giorgia, et al.
Publicado: (2021)

From CARs to TRUCKs and Beyond: Safely en Route to Adoptive T-cell Therapy for Cancer
por: Dummy
Publicado: (2016)

Fibroblasts Impair Migration and Antitumor Activity of NK-92 Lymphocytes in a Melanoma-on-Chip Model
por: Iaia, Ilenia, et al.
Publicado: (2022)

Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade
por: Serganova, Inna, et al.
Publicado: (2016)

Clinicopathologic Findings in Fatal Neurotoxicity After Adoptive Immunotherapy With CD19-Directed CAR T-Cells
por: Karschnia, Philipp, et al.
Publicado: (2021)

Ovarian Cancer Immunotherapy: Turning up the Heat
por: Ghisoni, Eleonora, et al.
Publicado: (2019)

Baseline Values of Circulating IL-6 and TGF-β Might Identify Patients with HNSCC Who Do Not Benefit from Nivolumab Treatment
por: Merlano, Marco Carlo, et al.
Publicado: (2023)

The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma
por: Pignochino, Ymera, et al.
Publicado: (2015)

Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy
por: Urak, Ryan, et al.
Publicado: (2017)

Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward
por: Jafarzadeh, Leila, et al.
Publicado: (2020)

Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities
por: Chen, Long, et al.
Publicado: (2022)

Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
por: Wu, Xinyu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t07f29brn7s2jdup40blnbo93m